The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...

The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...

The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...

The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...

The US drug regulator has missed a deadline for granting full approval to Novavax's COVID-19 vaccine, the company said ...

Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...

The FDA delays full approval for Novavax's COVID-19 vaccine, citing the need for additional data. Read more here.

Shares of Novavax Inc. NVAX slid 6.35% to $5.60 Thursday, on what proved to be an all-around dismal trading session for the ...

The FDA was scheduled to release its decision on Novavax’s updated, protein-based COVID-19 vaccine on April 1.

The delay dovetails with moves by Republican lawmakers in at least seven states to ban or limit mRNA vaccines. Some, ...

Bullish option flow detected in Novavax (NVAX) with 12,673 calls trading, 2x expected, and implied vol increasing almost 14 points to 90.76%.